Dr. Mitchell Felder, chief executive officer, founder and patent co- inventor of NanoLogix, commented, "We are very excited with the progressive development of our hydrogen bioreactor. High volumes of organic waste materials not only pose a threat to our environment, but its disposal causes a constant financial drain on cities, towns and industries nationwide. We believe our hydrogen bioreactor may present a meaningful, cost-effective, clean alternative to waste disposal. Through the use of our system, we intend to turn high-volume waste streams into an alternative fuel source, immediately enhancing our users' bottom-line. We look forward to protecting our unique technologies that enhance this process and prepare us for additional market introductions."

About NanoLogix, Inc.

NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to 32 patented technologies. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is presently operating a hydrogen bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious human diseases such as cancer, cystic fibrosis and AIDS, and owns a patent for the non-toxic induction of apoptosis ("cell suicide") for the treatment of cancer. For more information on the Company, visit http://www.nanologix.net.